Clinical proof of concept
In two Phase I/II trials in patients with advanced breast cancer or melanoma, MetXia was safe and well tolerated and demonstrated dose-dependent gene transfer. Results from a Phase I/II trial in 35 patients with non-resectable pancreatic cancer have shown disease stabilisation and associated stabilisation of tumour markers. Median survival for the 14 evaluable patients in this study, who received at least one dose of MetXia and three doses of CPA, was 27 weeks. Increased cycles of CPA appeared to be associated with longer survival.
|
 |
Market opporunity
Pancreatic cancer is the fifth leading cause of cancer-related mortality in the USA with over 30,000 deaths attributable to this disease annually. It is one of the most aggressive forms of cancer with a five-year survival rate in the low single percentage digits. The US pancreatic cancer drug market is expected to reach US$1.1 billion by 2013 (source: EPiQ Market Intelligence).
|
